GLP-1s Reduce Systemic Risk in Hidradenitis Suppurativa Patients

Patients with hidradenitis suppurativa (HS) who had previously used GLP-1 receptor agonists for diabetes or obesity demonstrated significantly reduced rates of multiple cardiovascular events and mortality, according to a large retrospective cohort study published this week. The study analyzed data from 11,984 patients diagnosed with HS, comparing those who had used GLP-1 receptor agonists (n=2,397) with a matched cohort who had not (n=9,587).

Researchers observed a notable decrease in the incidence of major adverse cardiovascular events (MACE) among GLP-1 agonist users. Specifically, the hazard ratio for MACE was 0.68 (95% CI, 0.51-0.91), indicating a 32% reduction in risk. This reduction was consistent across various cardiovascular outcomes, including myocardial infarction, stroke, and cardiovascular death.

The study, which utilized data from a large US commercial insurance claims database, aimed to investigate the potential systemic benefits of GLP-1 receptor agonists beyond their established roles in glycemic control and weight management. The findings suggest that these medications may offer a protective effect against cardiovascular complications in individuals with HS, a chronic inflammatory skin condition often associated with increased cardiovascular risk.

Further analysis revealed that the protective effect was observed regardless of the specific GLP-1 receptor agonist used or the duration of treatment. The study controlled for several confounding factors, including age, sex, comorbidities such as hypertension and hyperlipidemia, and the use of other cardiovascular medications. Despite these controls, the association between GLP-1 agonist use and reduced cardiovascular risk remained statistically significant. The authors suggest that the anti-inflammatory properties of GLP-1 receptor agonists, in addition to their metabolic benefits, might contribute to these observed systemic advantages in the HS population.